NEXIEN BIOPHARMA INC (NXEN) Financials
Newest figures come from the 10-Q for Q3 FY2025, filed May 14, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NXEN SEC filings page.
This page shows NEXIEN BIOPHARMA INC (NXEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
NEXIEN BIOPHARMA INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
NEXIEN BIOPHARMA INC reported -$30K in net income in Q3 2025. This represents an increase of 43.4% from the same quarter a year earlier.
NEXIEN BIOPHARMA INC earned $0.00 per diluted share (EPS) in Q3 2025. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q3 2025.
Not reported for Q3 2025.
Cash & Balance Sheet
NEXIEN BIOPHARMA INC held $8K in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
None of these metrics is reported for Q3 2025.
Capital Allocation
NEXIEN BIOPHARMA INC reported no research and development spending in Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
NXEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| SG&A Expenses | $5K-46.6% | N/A | $3K-93.5% | N/A | $9K-84.7% | $8K-88.3% | $46K-21.3% | N/A |
| Net Income | -$30K+43.4% | N/A | N/A | N/A | -$53K+33.4% | N/A | -$75K+21.0% | N/A |
| EPS (Basic) | $0.00-100.0% | $0.00 | $0.00+100.0% | $0.00+133.3% | $0.00+200.0% | $0.00 | $0.00+50.0% | -$0.01 |
| EPS (Diluted) | $0.00-100.0% | $0.00 | $0.00+100.0% | $0.00+133.3% | $0.00+200.0% | $0.00 | $0.00 | -$0.01 |
| Diluted Shares (Avg) | 71M+6.6% | 71M+8.7% | 70M+9.1% | N/A | 66M+6.0% | 65M+5.2% | 65M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Interest Expense, Income Tax.
NXEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8K-41.9% | $1K-50.1% | $5K-77.5% | $4K-90.3% | $14K-75.5% | $3K-96.6% | $22K-79.0% | $43K-65.4% |
| Current Assets | $8K-41.9% | $1K-50.1% | $5K-77.5% | $4K-90.3% | $14K-75.5% | $3K-96.6% | $22K-79.0% | $43K-65.4% |
| Cash & Equivalents | $8K-17.7% | $1K-50.1% | $5K-72.6% | $4K-88.1% | $10K-81.4% | $3K-96.2% | $18K-82.1% | $35K-69.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $459K+35.1% | $424K+33.8% | $397K+26.8% | $365K+23.8% | $340K+17.7% | $317K+13.4% | $313K+17.8% | $295K+21.9% |
| Current Liabilities | $459K+35.1% | $424K+33.8% | $397K+26.8% | $365K+23.8% | $340K+17.7% | $317K+13.4% | $313K+17.8% | $295K+21.9% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$451K-38.5% | -$423K-34.5% | -$392K-34.7% | -$361K-43.3% | -$325K-41.2% | -$314K-55.3% | -$291K-81.1% | -$252K-114.3% |
| Retained Earnings | -$11.6M-1.6% | -$11.6M-1.9% | -$11.6M-1.7% | -$11.5M-2.1% | -$11.4M-2.2% | -$11.4M-2.5% | -$11.4M-3.1% | -$11.3M-3.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NXEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
NXEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$361K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NEXIEN BIOPHARMA INC NXEN | FY2024 | N/A | N/A | N/A | $7K | — |
| KAYA HOLDINGS INC KAYS | FY2024 | $7K | N/A | N/A | $69K | — |
| CANN AMERICAN CORP CNNA | FY2012 | N/A | -$1.7M | N/A | $994K | — |
Where NEXIEN BIOPHARMA INC Ranks
Frequently Asked Questions
What are NEXIEN BIOPHARMA INC's total assets?
NEXIEN BIOPHARMA INC (NXEN) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.
What is NEXIEN BIOPHARMA INC's current ratio?
NEXIEN BIOPHARMA INC (NXEN) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Why is NEXIEN BIOPHARMA INC's debt-to-equity ratio negative or not reported?
NEXIEN BIOPHARMA INC (NXEN) has negative shareholder equity of -$361K as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.